In the same manner, the newly identified compounds may be combined with potentiators, as performed for cystic fibrosis patients carrying the F508del mutation40,41, since the potentiator VX-770/ivacaftor has been shown to partially correct the function of activity-defective class III ABCB4 variants42,43. The gene discussed is ABCB4; the disease is cystic fibrosis.